Legal & General Group
ACRS icon

Legal & General Group’s Aclaris Therapeutics ACRS Stock Holding History

Legal & General Group’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$30.9K Hold
8,242
– – ﹤0.01% 2826
2025
Q4 		$24.8K Hold
8,242
– – ﹤0.01% 2945
2025
Q3 		$15.7K Hold
8,242
– – ﹤0.01% 3147
2025
Q2 		$11.7K Buy
+8,242
New +$11.2K ﹤0.01% 3227
2024
Q2 		– Sell
-9,646
Closed -$12K – 3414
2024
Q1 		$12K Sell
9,646
-40,249
-81% -$48K ﹤0.01% 3161
2023
Q4 		$52.4K Hold
49,895
– – ﹤0.01% 2800
2023
Q3 		$342K Buy
49,895
+6,156
+14% +$52.6K ﹤0.01% 2585
2023
Q2 		$454K Buy
43,739
+22,691
+108% +$205K ﹤0.01% 2496
2023
Q1 		$170K Buy
21,048
+939
+5% +$11.9K ﹤0.01% 2641
2022
Q4 		$317K Buy
20,109
+485
+2% +$7.8K ﹤0.01% 2449
2022
Q3 		$308K Buy
19,624
+1,935
+11% +$30.5K ﹤0.01% 2468
2022
Q2 		$247K Buy
17,689
+1,088
+7% +$15.2K ﹤0.01% 2559
2022
Q1 		$286K Buy
16,601
+876
+6% +$11.9K ﹤0.01% 2550
2021
Q4 		$229K Buy
15,725
+107
+0.7% +$1.62K ﹤0.01% 2673
2021
Q3 		$281K Buy
15,618
+9,446
+153% +$151K ﹤0.01% 2581
2021
Q2 		$109K Buy
+6,172
New +$140K ﹤0.01% 2701
2020
Q2 		– Sell
-5,519
Closed -$6K – 3407
2020
Q1 		$6K Hold
5,519
– – ﹤0.01% 3234
2019
Q4 		$10K Hold
5,519
– – ﹤0.01% 3292
2019
Q3 		$6K Hold
5,519
– – ﹤0.01% 3314
2019
Q2 		$12K Sell
5,519
-976
-15% -$5.32K ﹤0.01% 3324
2019
Q1 		$39K Hold
6,495
– – ﹤0.01% 2801
2018
Q4 		$48K Buy
6,495
+2,536
+64% +$26.1K ﹤0.01% 2703
2018
Q3 		$57K Hold
3,959
– – ﹤0.01% 2703
2018
Q2 		$79K Sell
3,959
-27
-0.7% -$499 ﹤0.01% 2562
2018
Q1 		$70K Sell
3,986
-1,505
-27% -$31.9K ﹤0.01% 2605
2017
Q4 		$136K Sell
5,491
-181
-3% -$4.41K ﹤0.01% 2456
2017
Q3 		$146K Buy
5,672
+418
+8% +$11.2K ﹤0.01% 2449
2017
Q2 		$142K Buy
5,254
+2,605
+98% +$70.8K ﹤0.01% 2435
2017
Q1 		$79K Sell
2,649
-104
-4% -$3K ﹤0.01% 2672
2016
Q4 		$75K Buy
2,753
+1,115
+68% +$28.4K ﹤0.01% 2716
2016
Q3 		$42K Hold
1,638
– – ﹤0.01% 2601
2016
Q2 		$31K Buy
+1,638
New +$32.5K ﹤0.01% 2712

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Legal & General Group's ACRS Position: Q1 2026 in Review

Legal & General Group held its Aclaris Therapeutics (ACRS) position steady in Q1 2026 at 8,242 shares worth $30.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2826.

Legal & General Group first reported a position in ACRS in Q2 2016 and has held it in 32 quarters since. The position peaked at $454K in Q2 2023. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Legal & General Group held 8,242 shares of Aclaris Therapeutics worth $30.9K as of Q1 2026.
  • Legal & General Group left its Aclaris Therapeutics share count unchanged in Q1 2026.
  • Aclaris Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #2826 holding.
  • Legal & General Group first reported a position in Aclaris Therapeutics in Q2 2016 and has held it in 32 quarters since.
  • Legal & General Group's Aclaris Therapeutics position peaked at $454K in Q2 2023.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.